Ilginatinib

DB12784InvestigationalSmall molecule

NS-018 has been used in trials studying the treatment of Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, and Post-Essential Thrombocythemia Myelofibrosis.

Mechanism: Pharmacologically active on Tyrosine-protein kinase JAK2
Curator reviewed
Formula / weight: C₂₁H₂₀FN₇ · 389.438 g/mol (avg)
Also known as: (S)-N-(1-(4-FLUOROPHENYL)ETHYL)-4-(1-METHYL-1H-PYRAZOL-4-YL)-N'-(PYRAZIN-2-YL)PYRIDINE-2,6-DIAMINE · 2,6-PYRIDINEDIAMINE, N2-((1S)-1-(4-FLUOROPHENYL)ETHYL)-4-(1-METHYL-1H-PYRAZOL-4-YL)-N6-2-PYRAZINYL-
Code names: NS-018

Resolves to

Compound

UNII56R994WX4LCAS1239358-86-1ChEMBLCHEMBL4303389PubChem46866319

Structure

InChIKeyUQTPDWDAYHAZNT-AWEZNQCLSA-NSMILESC[C@H](NC1=CC(=CC(NC2=CN=CC=N2)=N1)C1=CN(C)N=C1)C1=CC=C(F)C=C1

Targets

O60674JAK2

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ilginatinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account